Orthocell Ltd (ASX: OCC) Share Price and News

Ms Wood is a plastic and reconstructive surgeon with more than 30 years'experience. Professor Wood was appointed a Member of the Order of Australia in 2003 and was named Australian of the Year in 2005 for her contribution to medicine and burns treatment.

Mr Anderson has more than 25 years'experience in medical devices and cellular therapeutics, with expertise in translating research into clinical and commercial products. His experience spans strategic planning, new product development, product launches, international regulatory pathways, reimbursement, marketing, sales and key opinion leader engagement. Paul previously held the Managing Director's position with Verigen Australia Pty Ltd, a human cell therapies company acquired by Nasdaq-listed Vericel Corporation, a multi-billion-dollar biotechnology company focused on cell therapies and specialty biologics. He has more than 20 years'experience in executive leadership and board roles and has experience in bringing regenerative medicine technologies from research through to clinical adoption and market entry.

Dr Thadhani is a recognised healthcare executive, physician and researcher with more than 30 years'experience in clinical medicine, research, medical administration and commercialisation. He is Executive Vice President, Chief Physician Executive and Dean of the Medical Faculty at Cedars-Sinai, where he cheks the organisation's academic and clinical enterprises. Dr Thadhani has authored more than 300 scientific publications and has experience in patient care, novel research programs, US regulatory pathways and the commercialisation of medical devices and therapeutics. He has served on multiple US FDA advisory committees and has acted as an adviser to a number of global pharmaceutical and healthcare organisations.

Mr Wielen is an executive leader with more than 30 years'experience across wealth management, private banking, investments and insurance. He has held senior roles with global financial services groups and has experience in capital markets, institutional investor engagement, acquisitions, integration and business transformation. He is also a senior adviser to Appian Capital Advisory LLP & Bridgewest Group.

Mr McNulty has more than 35 years'professional experience, including 22 years as a Deloitte partner and senior leadership roles across Deloitte Australia and Asia Pacific. He is also Vice-President and Board member of Cancer Council WA. He is the chairperson of the risk committee.

-

-

-

-